The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma

References

• Luminari S, Montanini A, Federico M. Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma. Hematol Rep 2011;3:e4.
   Google Scholar
• Visani G, Isidori A. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma:where we stand. Expert Rev Anticancer Ther 2009;9:357–363.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777–3784.
   PubMed Web of Science ®Google Scholar
• Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin Oncol 2006;33:S22–S27.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710–717.
   PubMed Web of Science ®Google Scholar
• Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 2012;157:159–170.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Issa DE, Visser O, et al. Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007. Ann Oncol 2012;23: 171–182.
   PubMed Web of Science ®Google Scholar
• Maartense E, Kluin-Nelemans HC, le Cessie S, et al. Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. Cancer 2000;89:2667–2676.
   PubMed Web of Science ®Google Scholar
• Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986;4:295–305.
   PubMed Web of Science ®Google Scholar
• Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996;22:483–493.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Chung JS, Song MK, et al. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 2012;69:1165–1172.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma 2012;53:581–588.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;(6):CD003917.
   PubMed Web of Science ®Google Scholar
• Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130:1–7.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, van der Pal HJ, Caron HN, et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2009;(4):CD005008.
   Web of Science ®Google Scholar
• van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;(3):CD005006.
   Google Scholar
• Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444–1454.
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25–36.
   PubMed Web of Science ®Google Scholar
• Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99;liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14: 239–246.
   PubMed Web of Science ®Google Scholar
• Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31:5–15.
   PubMed Web of Science ®Google Scholar
• Stavridi F, Palmieri C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev Anticancer Ther 2008;8:1859–1869.
   PubMed Web of Science ®Google Scholar
• Tulpule A, Espina BM, Berman N, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006;7:59–64.
   PubMedGoogle Scholar
• Visani G, Ferrara F, Alesiani F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma 2008;49:1081–1086.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high “life threat” impact cardiopathy. Br J Haematol 2011; 154:579–589.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Mappa S, Nassi L, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 2007;25:198–203.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Cernohous P, Engert A, et al. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol 2013;24:2618–2623.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma:a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012;13:696–706.
   PubMed Web of Science ®Google Scholar
• Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med 2005;352:2456–2457.
   Google Scholar
• Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330–352.
   PubMed Web of Science ®Google Scholar
• Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987;106:814–816.
   PubMed Web of Science ®Google Scholar
• Cohen M, Kronzon I, Lebowitz A. Reversible doxorubicin-induced congestive heart failure. Arch Intern Med 1982;142:1570–1571.
   PubMed Web of Science ®Google Scholar
• Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864–1871.
   PubMed Web of Science ®Google Scholar
• Bjelogrlic SK, Radic J, Jovic V, et al. Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. Basic Clin Pharmacol Toxicol 2005;97:311–319.
   PubMed Web of Science ®Google Scholar
• Roca-Alonso L, Pellegrino L, Castellano L, et al. Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology 2012;122:253–259.
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213–1225.
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112: 3754–3762.
   PubMed Web of Science ®Google Scholar
• Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422–1428.
   PubMed Web of Science ®Google Scholar
• Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007;7:129–134.
   PubMed Web of Science ®Google Scholar
• Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol 2012;30:1415–1421.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572–1582.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635–3643.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629–2636.
   PubMed Web of Science ®Google Scholar
• Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 2007;7:122–128.
   PubMed Web of Science ®Google Scholar
• Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 1973;33: 3024–3028.
   PubMed Web of Science ®Google Scholar
• Coltman CA Jr, Dahlberg S, Jones ES. CHOP is curative in thirty per cent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up. In Skarin AT, editor. Advances in cancer chemotherapy: update on treatment for diffuse large cell lymphoma. New York, NY: Park Row; 1986. pp. 71–77.
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
   PubMed Web of Science ®Google Scholar
• Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14:277–281.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041–3050.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
   PubMed Web of Science ®Google Scholar
• Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21: 2466–2473.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma:an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:1250–1259.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–633.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Kilickap S, Yavuz B, Aksoy S, et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med Oncol 2008;25:437–442.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–1022.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
   PubMed Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858–1867.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiapella A, Brusamolino E, et al. Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2–3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL). Blood 2012;120(Suppl. 1): Abstract 688.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma:a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009;94:1250–1258.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Storti S, et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995;19:329–335.
   PubMed Web of Science ®Google Scholar
• Pavlovsky S, Santarelli MT, Erazo A, et al. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol 1992;3:205–209.
   PubMed Web of Science ®Google Scholar
• Bezwoda W, Rastogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. Eur J Cancer 1995;31A:903–911.
   PubMed Web of Science ®Google Scholar
• Burton C, Smith P, Vaughan-Hudson G, et al. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol 2005;130:536–541.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530–2539.
   PubMed Web of Science ®Google Scholar
• Kasahara S, Hara T, Tsurumi H, et al. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011;52:629–634.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma:disease presentation, response to treatment, and survival--a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945–2953.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127–145.
   PubMed Web of Science ®Google Scholar
• Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther 2008;6:1311–1317.
   PubMedGoogle Scholar
• Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258–2262.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.
   PubMed Web of Science ®Google Scholar
• Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 2013;344:467–478.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661–667.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003; 88:888–894.
   PubMed Web of Science ®Google Scholar
• Lim ST, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48:374–380.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Herbrecht R, Wilhelm M, et al. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2011;52:620–628.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Cullis PR, et al. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990;53:183–190.
   PubMed Web of Science ®Google Scholar
• Kanter PM, Bullard GA, Ginsberg RA, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 1993;7:17–26.
   PubMedGoogle Scholar
• Gabizon A, Shmeeda H, Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci 2012;45:388–398.
   PubMed Web of Science ®Google Scholar
• Conley BA, Egorin MJ, Whitacre MY, et al. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol 1993;33:107–112.
   PubMed Web of Science ®Google Scholar
• Cowens JW, Creaven PJ, Greco WR, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993;53:2796–2802.
   PubMed Web of Science ®Google Scholar
• Batist G, Harris L, Azarnia N, et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006;17:587–595.
   PubMed Web of Science ®Google Scholar
• Chan S, Davidson N, Juozaityte E, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004;15:1527–1534.
   PubMed Web of Science ®Google Scholar
• Valero V, Buzdar AU, Theriault RL, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999;17:1425–1434.
   PubMed Web of Science ®Google Scholar
• Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010;21:1492–1499.
   PubMed Web of Science ®Google Scholar
• Dell’Olio M, Scalzulli RP, Sanpaolo G, et al. Non-pegylated liposomal doxorubicin (Myocet(R)) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2011;52:1222–1229.
   PubMed Web of Science ®Google Scholar
• Gimeno E, Sanchez-Gonzalez B, Alvarez-Larran A, et al. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leuk Res 2011;35:358–362.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Vige D, Coughlin SS, et al. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 1993; 7:572–579.
   PubMed Web of Science ®Google Scholar
• Heintel D, Skrabs C, Hauswirth A, et al. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol 2010;89: 163–169.
   PubMed Web of Science ®Google Scholar
• Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012;30:4091–4097.
   PubMed Web of Science ®Google Scholar
• Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 2008;8:21–32.
   PubMedGoogle Scholar
• Schmitt CJ, Dietrich S, Ho AD, et al. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Ann Hematol 2012;91:391–397.
   PubMed Web of Science ®Google Scholar
• Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002;87:822–827.
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Castaneda C, et al. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol 2002;19:55–58.
   PubMed Web of Science ®Google Scholar
• Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47:2174–2180.
   PubMed Web of Science ®Google Scholar
• Carver JR, Schuster SJ, Glick JH. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities. J Clin Oncol 2008; 26:3122–3124.
   PubMed Web of Science ®Google Scholar
• He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996–1002.
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:3159–3165.
   PubMed Web of Science ®Google Scholar
• Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity:course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039–1058.
   PubMed Web of Science ®Google Scholar
• Andersson A, Naslund U, Tavelin B, et al. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention. Int J Cancer 2009;124:1914–1917.
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–905.
   PubMed Web of Science ®Google Scholar
• Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 2012;19:377–388.
   PubMed Web of Science ®Google Scholar
• Bovelli D, Plataniotis G, Roila F, et al. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(Suppl. 5): v277–v282.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl. 7):vii155–vii166.
   PubMed Web of Science ®Google Scholar
• Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment:strategies for early detection. Lancet Oncol 2009;10:391–399.
   PubMed Web of Science ®Google Scholar
• Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer 2008;16:437–445.
   PubMed Web of Science ®Google Scholar
• Pudil R, Horacek JM, Strasova A, et al. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol 2008;30:160–162.
   PubMedGoogle Scholar
• Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007;29:309–313.
   PubMedGoogle Scholar
• Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–2754.
   PubMed Web of Science ®Google Scholar
• Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318–326.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–220.
   PubMed Web of Science ®Google Scholar
• Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011;22:257–267.
   PubMed Web of Science ®Google Scholar